US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIMPLIFY MANAGED FUTURES STRATEGY ETF

28.14

-0.0200-0.07%

Post-market: 28.140.00000.00%16:04 EDT

Volume:311.00K

Turnover:8.74M

Market Cap:- -

PE:- -

High:28.18

Open:28.06

Low:28.00

Close:28.16

Loading ...

Overview Company News Filings

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

Wolters Kluwer 2024 Full-Year Report

Voyager Provides Update on SOD1 ALS Gene Therapy Program

Excluding Ixom’s capital optimisation, KIT’s DPU rose 1% y-o-y in FY2024, but total DPU shows sharp decline

The Edge Singapore

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Press Release: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Coming back to CES after a decade-long break was a trip

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?

Wave Life Sciences announces submission of CTA for WVE-007

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025

Intelligent Product Solutions Partners with The Digital Medicine Society (DiMe) Initiative to Advance Digitally-Enabled Hospital-at-Home Care

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","market":"US","secType":"STK","nameCN":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","latestPrice":28.14,"timestamp":1749758400000,"preClose":28.16,"halted":0,"volume":311002,"hourTrading":{"tag":"盘后","latestPrice":28.14,"preClose":28.14,"latestTime":"16:04 EDT","volume":47901,"amount":1347934.14,"timestamp":1749758658081},"delay":0,"floatShares":38775001,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-0.02,"latestTime":"06-12 16:00:00 EDT","open":28.06,"high":28.1795,"low":27.9968,"amount":8743648.062354,"amplitude":0.006488,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749801600000},"marketStatusCode":0,"adr":0,"exchange":"AMEX","adjPreClose":28.16,"sharesOutstanding":38775001,"nav":28.13,"aum":1090805363.52,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.14,"preClose":28.14,"latestTime":"16:04 EDT","volume":47901,"amount":1347934.14,"timestamp":1749758658081},"volumeRatio":0.88456,"impliedVol":0.2398,"impliedVolPercentile":0.7619},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","floatShares":38775001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.88456,"shares":0,"dividePrice":0,"high":28.1795,"amplitude":0.006488,"preClose":28.16,"low":27.9968,"week52Low":25.6601,"pbRate":"--","week52High":30.213,"institutionHeld":0,"latestPrice":28.14,"eps":0,"divideRate":0,"volume":311002,"delay":0,"ttmEps":0,"open":28.06,"prevYearClose":27.89,"prevWeekClose":27.92,"prevMonthClose":27.11,"prevQuarterClose":29.6,"fiveDayClose":27.53,"twentyDayClose":27.62,"sixtyDayClose":29.61},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516533666","title":"Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516533666","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516533666?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:05","pubTimestamp":1741035900,"startTime":"0","endTime":"0","summary":"Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March  03, 2025  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clini","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3036046/0/en/Pliant-Therapeutics-Provides-Corporate-Update-and-Reports-Fourth-Quarter-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","FVC","CTA","BK4139"],"gpt_icon":0},{"id":"2514983992","title":"Immunocore reports fourth quarter and full year 2024 financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514983992","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514983992?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"KIMMTRAK  Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025. Executing on KIMMTRAK lifecycle management with two Phase 3 trials  in additional melanoma indications. Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C . First patient dosed in Phase 1/2 trial of IMC-R117C  in colorectal and other gastrointestinal cancers. CTA/IND on track for IMC-S118AI  in 2H 2025 and for IMC-U120AI, our first non-HLA-restricted candidate initially for atopic dermatitis, in 2026. Cash, cash equivalents and marketable securities of $820.4 million as of December 31, 2024. “In 2024, we continued to grow KIMMTRAK sales, execute on our KIMMTRAK lifecycle management program, advance our deep clinical pipeline, and expand into autoimmune diseases, supported by a strong cash position and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunocore-reports-fourth-quarter-full-120000489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATOM","IE00B66KJ199.SGD","BK4006","BK4588","PFS","BK4585","LU1878469433.USD","BK4567","BK4007","CRS","CM","MTD","BK4505","LU1093756325.SGD","LU2065731478.USD","BK4147","IE0031619046.USD","IE00B7SZL793.SGD","CTA","BK4599","IE00BYQQ9H92.USD","LU1721428933.USD","PROC","BK4097","BK4139","ORR","BK4207","ALT","BK4211","BK4121","LU0347712357.USD","BK4195","OS","IMCR","LU2413666426.HKD","BK4533","LU1093756168.USD","IE00BFXG0V08.USD","IE00B19Z4B17.USD","BK4548","LU2413666699.HKD"],"gpt_icon":0},{"id":"2514009958","title":"Wolters Kluwer 2024 Full-Year Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2514009958","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514009958?lang=en_us&edition=fundamental","pubTime":"2025-02-26 15:00","pubTimestamp":1740553200,"startTime":"0","endTime":"0","summary":"Alphen aan den Rijn, February 26, 2025 – Wolters Kluwer, a global leader in professional information solutions, software and services, today releases its full-year 2024 results.Revenues 5,916 million, up 6% in constant currencies and up 6% organically.Recurring revenues  up 7% organically; non-recurring trends varied.Adjusted operating profit 1,600 million, up 8% in constant currencies.Diluted adjusted EPS 4.97, up 9% overall and up 11% in constant currencies.Adjusted free cash flow 1,276 million, up 9% in constant currencies, ahead of expectation.Net-debt-to-EBITDA of 1.6x; return on invested capital  improved to 18.1%.Proposed 2024 total dividend 2.33 per share, an increase of 12%.Nancy McKinstry, CEO and Chair of the Executive Board, commented: “Wolters Kluwer delivered another year of 6% organic growth and a further increase in the adjusted operating profit margin. Recurring revenues, in particular cloud software subscriptions, continued to be the main driver of our growth. We main","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wolters-kluwer-2024-full-report-070000393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BOLD","LU0130517989.USD","LU1165135440.EUR","LU2417539215.USD","BK4231","BK4106","LU0702159343.USD","E","D","LU2456880835.USD","BK4156","LU2360032135.SGD","BK4523","CTA","ROIC","LU1543694498.USD","BK4555","WTKWY","LU1668664300.SGD","BK4567","BK4585","LU2236285917.USD","LU1166156734.SGD","LU2125154778.USD","IE00BN0W2T93.GBP","GHG","G","J","K","BK4139","LU0347712357.USD","LU0477156953.USD","BK4080","LU0320765646.SGD","BK4207","WOLTF","A","BK4212","LU1201861249.SGD","LU1721428933.USD","IE00BSNM7G36.USD","BK4574","H","LU2092937221.SGD","IE00BZ18W340.USD","DRIP","LU0052756011.USD","LU0098860793.USD","F"],"gpt_icon":0},{"id":"2510005378","title":"Voyager Provides Update on SOD1 ALS Gene Therapy Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2510005378","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510005378?lang=en_us&edition=fundamental","pubTime":"2025-02-11 20:00","pubTimestamp":1739275200,"startTime":"0","endTime":"0","summary":"- Company to assess alternate payloads; no changes planned to novel capsid component -  - Resulting shift of timeline and costs extends cash runway into mid-2027 –   - All other programs remain on tra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/11/3024034/36461/en/Voyager-Provides-Update-on-SOD1-ALS-Gene-Therapy-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA"],"gpt_icon":0},{"id":"2508455190","title":"Excluding Ixom’s capital optimisation, KIT’s DPU rose 1% y-o-y in FY2024, but total DPU shows sharp decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2508455190","media":"The Edge Singapore ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508455190?lang=en_us&edition=fundamental","pubTime":"2025-02-04 00:49","pubTimestamp":1738601347,"startTime":"0","endTime":"0","summary":"Keppel Infrastructure Trust announces sharp decline in total DPU, but 1% y-o-y growth in DPU excluding 2.33 cents from Ixom's capital optimisation ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/capital/results/excluding-ixoms-capital-optimisation-kits-dpu-rose-1-y-o-y-fy2024-total-dpu-shows?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["SGXZ43160589.SGD","LU0516422952.EUR","SG9999001127.SGD","LU0516422366.SGD","SG9999000343.SGD","SG9999014302.SGD","SG9999014484.SGD","SG9999002950.SGD","LU1242518857.USD","SG9999013460.SGD","SGXZ58947870.SGD","SG9999014492.USD","CTA","SG9999008742.SGD","SG9999004360.SGD","SG9999003826.SGD","SG9999013486.USD","SGXZ27511609.SGD","BK6501","SG9999006266.SGD","LU0516422440.USD","BK6031","SG9999000475.SGD","BK6505","SG9999001069.SGD","SG9999013478.USD","LU0979878070.USD","BK6111","SG9999001135.SGD","SG9999005177.SGD","A7RU.SI","BN4.SI","BK6102","SG9999003461.SGD","LU0516423091.SGD","LU1242518931.SGD","SG9999016042.SGD","SGXZ24219693.SGD","LU0516423174.USD","BK6523","NEA"],"gpt_icon":0},{"id":"2507957125","title":"Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507957125","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507957125?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:01","pubTimestamp":1738328460,"startTime":"0","endTime":"0","summary":"Prioritizing Revita’s clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1 pivotal study; anticipate midpoint da","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/31/3018773/0/en/Fractyl-Health-Announces-Increased-Focus-on-Groundbreaking-Revita-Weight-Maintenance-and-Rejuva-Pancreatic-Gene-Therapy-Programs-with-Potential-to-Deliver-Key-Clinical-Milestones-A.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GUTS","CTA"],"gpt_icon":0},{"id":"2503997818","title":"Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2503997818","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503997818?lang=en_us&edition=fundamental","pubTime":"2025-01-16 21:55","pubTimestamp":1737035700,"startTime":"0","endTime":"0","summary":"MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing Appro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/16/3010810/0/en/Metagenomi-Highlights-Progress-Across-Therapeutic-Portfolio-and-Outlines-Anticipated-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGT","BK4139","PRGS","LU2065732104.USD","BK4097","CTA","BK4109","ASH","LU2463526074.USD","MGX"],"gpt_icon":0},{"id":"2503677942","title":"Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2503677942","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503677942?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:05","pubTimestamp":1736975100,"startTime":"0","endTime":"0","summary":"- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - FA: First-in-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/15/3010436/0/en/Solid-Biosciences-Outlines-Key-Priorities-for-Advancing-Diversified-Neuromuscular-and-Cardiac-Development-Pipeline-and-Establishing-Leadership-in-Precision-Genetic-Medicines.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU2089283258.USD","LU0106831901.USD","BK4139","LU0314104364.USD","LU1732799900.SGD","LU0098860793.USD","BK4144","IE00BZ1G4Q59.USD","LU2111349929.HKD","LU1989772923.USD","BK4539","BK4588","LU0158827781.USD","LU1732800096.USD","FA","GENE","GLP","LU0106261372.USD","BK4121","CTA","LU2347655156.SGD","MDCO","LU1720051108.HKD","LU0225283273.USD","LU2271345857.HKD","LU1363072403.SGD","LU0267386448.USD","LU0912757837.SGD","BK4585","BK4504","LU0795875169.SGD","LU0971096721.USD","BK4534","LU2023251221.USD","LU1989772840.SGD","BK4127","LU1162221912.USD","LU1074936037.SGD","SLDB","IE00BKVL7J92.USD","BK4516","LU0006306889.USD","LU2357305700.SGD","LU2089284900.SGD","IDN","BK4023","BK4590","LU0795875086.SGD","BK4130"],"gpt_icon":0},{"id":"2503147307","title":"Press Release: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2503147307","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503147307?lang=en_us&edition=fundamental","pubTime":"2025-01-13 22:00","pubTimestamp":1736776800,"startTime":"0","endTime":"0","summary":"Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities. -- Achieved in vivo preclinical proof of concept of editing hematopoietic. stem cells in non-human primates as a key step toward developing a novel. in vivo treatment for sickle cell disease and beta thalassemia. -- Achieved in vivo editing of liver cells in non-human primates and in vivo. delivery to two additional cell types in humanized mice. -- Anticipated 2025 milestones include: declare two in vivo development. candidates, one in HSCs and one in liver; present further in vivo HSC. data; present in vivo data in one liver indication; establish one. additional target cell type/tissue; and continue to derive revenue. New In Vivo Proof of Concept Data in Non-human Primates and Humanized Mice Highlighting the Potential of Editas' Gene Upregulation Strategy Across Tissues","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4139","LU1861558580.USD","CTA","EDIT","BK4585","LU1861559042.SGD","PACI.U","CRSP","BK4588"],"gpt_icon":0},{"id":"2502809389","title":"Coming back to CES after a decade-long break was a trip","url":"https://stock-news.laohu8.com/highlight/detail?id=2502809389","media":"The Verge","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502809389?lang=en_us&edition=fundamental","pubTime":"2025-01-11 13:00","pubTimestamp":1736571600,"startTime":"0","endTime":"0","summary":"Twelve years ago, I could have told you exactly what happened at my first CES and what happened at my third. Each was a chapter with a beginning, middle, and end; the lines between them drawn clearly.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theverge.com/2025/1/11/24340285/ces-2025-robots-ai-sphere","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theverge_highlight","symbols":["BK4535","LVCC","SG9999014898.SGD","GB00BDT5M118.USD","BK4551","LU0353189763.USD","BK4588","IE00B19Z3581.USD","BK4503","SG9999015986.USD","SGXZ31699556.SGD","LU0353189680.USD","LU0719512351.SGD","LU1064131342.USD","LU0106261372.USD","IE00B7SZLL34.SGD","LU2087625088.SGD","LU1316542783.SGD","SG9999018857.SGD","LU1983260115.SGD","UBER","LU0127658192.USD","IE0002270589.USD","BK4022","SG9999018865.SGD","SG9999017495.SGD","SG9999015978.USD","BK4550","IE00B19Z3B42.SGD","LU0006306889.USD","SG9999014880.SGD","BK4230","LU1814569148.SGD","BK4505","LU1988902786.USD","SG9999014914.USD","BK4536","LU0082616367.USD","CTA","SG9999014906.USD","IE00BZ199S13.USD","SG9999015952.SGD","LU0642271901.SGD","SG9999015945.SGD","BK4585","LU2264538146.SGD"],"gpt_icon":1},{"id":"2502614022","title":"Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2502614022","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502614022?lang=en_us&edition=fundamental","pubTime":"2025-01-10 05:00","pubTimestamp":1736456400,"startTime":"0","endTime":"0","summary":"Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3007342/0/en/Mural-Oncology-Highlights-Pipeline-Progress-and-Anticipated-2025-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROC","BK4007","PRGS","MURA","BK4139","BK4097","CTA","OS","LU2065732104.USD"],"gpt_icon":0},{"id":"2495509646","title":"Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec","url":"https://stock-news.laohu8.com/highlight/detail?id=2495509646","media":"Business Wire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495509646?lang=en_us&edition=fundamental","pubTime":"2024-12-31 05:15","pubTimestamp":1735593300,"startTime":"0","endTime":"0","summary":"- Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential new collaboration partner. \"Giroctocogene fitelparvovec has demonstrated the potential to be a life changing gene therapy treatment for hemophilia A patients, and following positive results from the Phase 3 AFFINE trial, we believe it is well positioned for regulatory submissions and potential commercialization,\" said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. \"While we were surprised and extremely disappointed by Pfizer’s decision to end our collaboration so close to the anticipated BLA and MAA submissions, especially given the compelling pivotal clinical trial data, we appreciate their collaboration in leading a robust and successful clinical development program and for advancing the asset to this important stage. We are committed to exploring the optimal path forward for th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sangamo-therapeutics-regain-full-rights-211500999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","LU1066051498.USD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","IE00BBT3K403.USD","SG9999001176.SGD","SG9999003800.SGD","ABR","LU0306806265.USD","BK4592","BK4581","PFE","SG9999013999.USD","BK4568","LU0321505868.SGD","SG9999001176.USD","BK4110","CTA","MAA","SG9999002232.USD","LENZ","IE00B19Z3581.USD","SGMO","LU0234572021.USD","LU1894683264.USD","LU1894683348.USD","BK4007","LU0306807586.USD","LU1057294990.SGD","LU1066053197.SGD","LU0058720904.USD","LU0321505439.SGD","BK4533","SG9999002224.SGD","LU1023059063.AUD","BK4585","LU0456855351.SGD","IE000M9KFDE8.USD","BK4139","BK4550","BK4599","LU0985481810.HKD","IE0002270589.USD","LU0868494617.USD","SG9999011175.SGD","LU1883839398.USD","LU0225284248.USD","LU0122379950.USD","BK4588","IE00BLSP4239.USD"],"gpt_icon":1},{"id":"2495588049","title":"Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2495588049","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495588049?lang=en_us&edition=fundamental","pubTime":"2024-12-29 19:25","pubTimestamp":1735471558,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now.In this article, we are going to take a look at where Prime Medicine, Inc. stands against the other gene therapy stocks.As per IMARC, healthcare infrastructure in the US adapted to accommodate gene therapies. As per IQVIA’s tally, 114 gene therapy trials were initiated in the year 2023. Out of this, a large majority  were sponsored by the healthcare industry. As per Kella Kapnisi, Head of Cell and Gene Therapy at Team Consulting , as of now, there are38 cell and gene therapies approved by the FDA. Notably, many of these have reached commercialization through mostly manual laboratory manufacturing processes.As per IMARC, the collaborations between biotech companies, pharmaceutical firms, and university research institutes can pool the funds needed to address challenges related to creating and promoting gene treatments.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prime-medicine-inc-prme-gene-112558617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","BK4139","NVIW.SI","CTA","PSQ","QLD","MNQmain","TQQQ","TSYW.SI","QID","SQQQ","PRME","NQmain","USAW.SI","USJW.SI"],"gpt_icon":1},{"id":"2493750195","title":"Wave Life Sciences announces submission of CTA for WVE-007","url":"https://stock-news.laohu8.com/highlight/detail?id=2493750195","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493750195?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:40","pubTimestamp":1734961219,"startTime":"0","endTime":"0","summary":"Wave Life Sciences (WVE) announced the submission of its first clinical trial application, CTA, for WVE-007 in obesity. WVE-007 is an investigation...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-announces-submission-of-cta-for-wve-007?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wave-life-sciences-announces-submission-of-cta-for-wve-007?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CTA","WVE"],"gpt_icon":0},{"id":"2492900080","title":"Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B","url":"https://stock-news.laohu8.com/highlight/detail?id=2492900080","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492900080?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:01","pubTimestamp":1734523260,"startTime":"0","endTime":"0","summary":"- Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA approval for PBGENE-HBV in 2024. \"We are pleased to receive our second CTA approval for PBGENE-HBV, expanding our ELIMINATE-B trial into a world-class HBV clinical trial site in Hong Kong,\" said Dr. Murray Abramson, Senior Vice President, Head of Clinical Development of Precision BioSciences. \"PBGENE-HBV has been designed to target a viral site that is prevalent across all HBV genotypes, including in Asia, and we believe that this will enable us to evaluate and provide access to as many patients as possible. In addition to Hong Kong, our clinical trial site in Moldova continues to execute as planned, and we look forward to sharing clinical data as it matures throughout 2025.\". Through its precision cutting, compact design, and simple structure, PBGENE-HBV is engineered to target the HBV viral genome and drive functional","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vrgaD_Pt49bwoCl_NBdEqw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ab160baedd3ce978e40c2709d3dad7d3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vrgaD_Pt49bwoCl_NBdEqw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ab160baedd3ce978e40c2709d3dad7d3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/precision-biosciences-receives-approval-hong-120100591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTA","BK4139","DTIL"],"gpt_icon":0},{"id":"2492962857","title":"3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492962857","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492962857?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:59","pubTimestamp":1734443940,"startTime":"0","endTime":"0","summary":"Innovation holds the key in the ever-evolving biotech sector, and most companies in this sector are striving to develop a drug or treatment using a breakthrough technology.Biotech companies with promising gene therapies in their portfolio/pipeline have garnered investors’ attention in 2024. Interest in this space renewed following the FDA approval of a few gene therapies toward the end of 2023.Consequently, some pharma/biotech bigwigs scurried for a lucrative catch in the space, either through licensing deals or acquisitions.Gene therapy enables the modification of a patient’s gene to treat or cure the underlying disease. The treatment involves either replacing a disease-causing gene with a healthy copy of the gene or disabling a disease-causing gene that is not functioning properly. A new or modified gene can also be introduced into the patient’s body to help treat a disease.The therapy takes a different approach from traditional drug therapies as it can treat the underlying cause and","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OQmIpr5vwbHDcZeUdtSZeA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a85ded772dcf5689bab3fdbf2b5da21","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OQmIpr5vwbHDcZeUdtSZeA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a85ded772dcf5689bab3fdbf2b5da21"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-biotech-stocks-promising-gene-135900489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4556","BK4139","IE00BJT1NW94.SGD","IE0002141913.USD","SRPT","IE00BFTCPJ56.SGD","LU1861558580.USD","CTA","VYGR","BK4585","IE0009355771.USD","IE00BJJMRZ35.SGD","LU1861559042.SGD","CRSP","BK4588","IE00B2B36J28.USD"],"gpt_icon":1},{"id":"2492095704","title":"Intelligent Product Solutions Partners with The Digital Medicine Society (DiMe) Initiative to Advance Digitally-Enabled Hospital-at-Home Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2492095704","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492095704?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:52","pubTimestamp":1734443520,"startTime":"0","endTime":"0","summary":"HAUPPAUGE, N.Y., Dec.  17, 2024  (GLOBE NEWSWIRE) -- Intelligent Product Solutions (IPS), an award-winning product design firm, today announced its partnership in the Advancing a Sustainable Hospital-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998297/0/en/Intelligent-Product-Solutions-Partners-with-The-Digital-Medicine-Society-DiMe-Initiative-to-Advance-Digitally-Enabled-Hospital-at-Home-Care.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FORD","HBCP","BK4202","BK4211","IPS","BK4195","CTA"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":37,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTA\",params:#limit:5,,,undefined,":[{"date":"2025-03-26","symbol":"CTA","amount":0.12,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-31"},{"date":"2024-12-23","symbol":"CTA","amount":0.73816,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-31"},{"date":"2024-09-25","symbol":"CTA","amount":0.3,"announcedDate":"2024-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-25","defaultRemindTime":1727271000000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-30","payableDate":"2024-09-25","currency":"USD","dateTimestamp":1727236800000,"payDate":"2024-09-30"},{"date":"2024-06-25","symbol":"CTA","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-06-28"},{"date":"2024-03-25","symbol":"CTA","amount":0.15,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-26","defaultRemindTime":1711373400000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","recordDate":"2024-03-28","payableDate":"2024-03-26","currency":"USD","dateTimestamp":1711339200000,"payDate":"2024-03-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTA\",market:\"US\",,,undefined,":[{"executeDate":"2022-08-26","recordDate":"2022-08-29","paymentDate":"2022-08-31","value":0.15,"currency":"USD"},{"executeDate":"2022-09-27","recordDate":"2022-09-28","paymentDate":"2022-09-30","value":0.15,"currency":"USD"},{"executeDate":"2022-10-26","recordDate":"2022-10-27","paymentDate":"2022-10-31","value":0.15,"currency":"USD"},{"executeDate":"2022-11-25","recordDate":"2022-11-28","paymentDate":"2022-11-30","value":0.15,"currency":"USD"},{"executeDate":"2022-12-27","recordDate":"2022-12-28","paymentDate":"2022-12-30","value":1.11096,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTA\",market:\"US\",delay:false,,,undefined,":{}}}